Anatomy of Exploitation: How Global Cancer Drugmakers Prioritize Profits Over Patients Despite Multi-Billion-Dollar Penalties

Main Facts

For millions of people diagnosed with cancer worldwide, a positive prognosis often hinges on access to modern, high-cost medicines. Yet, an exhaustive global investigation by the International Consortium of Investigative Journalists (ICIJ)—incorporating civil and criminal enforcement cases across 31 countries—reveals that the pharmaceutical industry operates within a fundamentally broken healthcare system. Major cancer drug manufacturers repeatedly engage in illegal marketing, anti-competitive practices, fraudulent kickback schemes, and patent abuses.

Between 2010 and 2025, 12 major multinational pharmaceutical companies resolved 25 separate cases with regulatory authorities across 10 countries, paying nearly $1.7 billion in total fines and settlements. However, these financial penalties represent a minuscule fraction—roughly one-third of 1%—of the nearly $696 billion accrued in revenue by these corporations during the years the settlements were finalized.

Experts and whistleblowers argue that these recurring penalties do not act as effective deterrents. Instead, they function merely as an accepted, low-cost "fee for doing business," allowing pharmaceutical giants to continuously extract massive profits at the direct expense of patients, taxpayers, and overburdened global healthcare systems.

Chronology of Corporate Misconduct and Enforcement

The systemic patterns of regulatory infractions and subsequent enforcement actions span decades, illustrating a continuous loop of alleged misconduct, legal settlements, and corporate restructuring:

• 2003: Bristol Myers Squibb pays $5.5 million to settle multi-state anti-competition charges related to cancer therapeutics.
• 2005 (The Schering-Plough Case): Schering-Plough Corp. pleads guilty to a criminal conspiracy regarding false statements and off-label marketing for the brain cancer drug Temodar (Temodal) and the cancer therapy Intron A, agreeing to a $435 million criminal and civil penalty. (Schering-Plough was later acquired by Merck).
• 2010: Novartis enters a five-year corporate integrity agreement and pays $237 million to resolve civil claims alleging illegal kickbacks to physicians to boost prescriptions for drugs including Sandostatin.
• 2013: Celgene employees are allegedly trained to push the multiple myeloma drugs Revlimid and Thalomid for unapproved indications, exposing patients to severe side effects.
• 2015: Following investigations into illegal specialty pharmacy kickbacks, the U.S. government extends Novartis’s corporate integrity agreement by five years as part of a $390 million settlement.
• 2016: Tobeka Daki dies at age 49 in South Africa after being priced out of Roche’s breast cancer drug Herceptin, which cost roughly $36,000 annually—four times the average South African household income. Her death ignites an international pricing campaign and government probe.
• 2017: Celgene pays a historic $280 million to settle U.S. federal and state allegations of off-label promotion of Revlimid and Thalomid.
• 2018: Pfizer pays $23.85 million to resolve allegations that it funneled illegal copay assistance through a charitable foundation to boost sales of its kidney cancer medications, Sutent and Inlyta.
• 2020:
  • Novartis agrees to a $51 million settlement with the U.S. Justice Department regarding kickback allegations tied to the kidney cancer drug Afinitor, signing its third corporate integrity agreement.
  • Antitrust authorities in Romania fine Roche a combined $14 million for manipulating drug pricing and blocking generic competition for MabThera, Herceptin, and Tarceva.
• 2021:
  • Incyte Corp. agrees to pay $12.6 million to resolve Department of Justice allegations of paying illegal kickbacks to a charitable foundation to artificially inflate prescriptions of the leukemia and myelofibrosis drug Jakafi.
  • Austrian regulators penalize Merck with a "commitment decision" without a fine after accusing the company of predatory hospital pricing for Temodal to block generic competitors.
• 2024: Bristol Myers Squibb pays $2.7 million to settle anti-competition allegations in Israel concerning multiple myeloma medications.

Supporting Data and Financial Analysis

The empirical data compiled by ICIJ, alongside public datasets from accountability groups such as Good Jobs First and Public Citizen, highlights the structural inadequacy of current regulatory punishments:

• Revenue Disconnect: Across the 12 investigated drugmakers, total healthcare-related fines and settlements accumulated between 2010 and 2025 reached $15.4 billion. However, these same companies posted more than $491 billion in revenue in their most recent fiscal year alone.
• Recidivism Rates: According to research by business ethics professor Denis Arnold of the University of North Carolina, 85% of surveyed large drugmakers have paid statutory penalties, with most engaging in illegal activities continuously for four years or more. Six of the 12 pharmaceutical giants analyzed by ICIJ were implicated in infractions involving multiple cancer drugs.
• The Patent Web: Companies protect their revenue streams not only through off-label marketing and kickbacks, but also via aggressive "evergreening" patent strategies. For example, Merck’s blockbuster immunotherapy drug Keytruda has been wrapped in a dense web of over 1,200 patent applications across 53 countries and territories to artificially delay cheaper biosimilars from entering the market.
• Enforcement Slump: Public Citizen research indicates that criminal prosecutions of major pharmaceutical companies declined significantly following the Obama administration, with regulatory resources later shifting toward the opioid epidemic and various enforcement freezes implemented under subsequent political administrations.

Official Responses

Representatives for the major pharmaceutical companies have consistently defended their commercial practices while declining liability in ongoing investigations:

• Roche: Strongly denies abusing market dominance, asserting that its global business practices are completely proper, lawful, and compliant. The company declined to comment on active regulatory enforcement proceedings in Belgium and South Africa.
• Novartis: Maintains that it has undergone a cultural transformation toward strict ethics and integrity. Following its 2020 settlements, former general counsel Shannon Thyme Klinger emphasized the company’s commitment to operating with high values and building societal trust.
• Bristol Myers Squibb / Celgene: While Celgene historically denied wrongdoing prior to its acquisition, Bristol Myers Squibb has continued to resolve various international anti-competition and market exclusivity challenges through financial settlements without admitting direct liability.
• Pfizer and Incyte: Both companies settled past federal allegations under terms that explicitly avoided admissions of guilt or wrongdoing, choosing instead to resolve matters to avoid prolonged litigation while pledging compliance improvements.

Independent legal and medical experts, however, remain deeply critical of these official postures. Whistleblower attorney Reuben Guttman characterized corporate integrity agreements as "pieces of paper," stating bluntly: "What these companies are doing… they’re basically paying a fee for the license to break the law." Dr. Reshma Ramachandran of the Yale School of Medicine added that these financial settlements are "effectively a slap on the wrist that the companies largely ignore," treating penalties as a standard operational overhead cost.

Implications for Global Healthcare and Patients

The human toll of these corporate strategies is borne directly by patients, families, and global public health infrastructures.

In South Africa, the legacy of activist Tobeka Daki—who died in 2016 from spinal cancer after being unable to afford Roche’s Herceptin—continues to fuel grassroots movements. Her close friend and fellow activist, Babalwa Malgas, who has battled cancer three times, summarized the core injustice of the system: "Our slogan was: My cancer, your profit. We learned of greed from Roche."

Similarly, patients in high-income nations face profound financial toxicity. Beth Kitchin, a 62-year-old retired nutrition professor from Alabama diagnosed with leukemia, expressed shock upon learning that her prescribed maintenance medication, Jakafi, had been the subject of a federal kickback investigation. Holding up a tiny bottle of pills, she noted, "That’s like a $300 pill right there. It’s a game."

Rebecca Hall, a California-based cancer survivor who relies entirely on Roche’s Herceptin to stay alive, voiced deep frustration over the inadequacy of punitive fines. She suggested a fundamental shift in how justice is administered: "Can you imagine if all of the settlement money had been put into a fund that was to benefit patients who couldn’t afford their medications? That would change the game."

Ultimately, as global cancer rates climb, the current framework of regulatory fines and non-prosecution agreements fails to deter systemic violations. Without structural reforms to patent laws, transparent pricing mechanisms, and severe penalties that threaten corporate survival rather than corporate profit margins, the global pharmaceutical giants will remain unchecked in prioritizing their bottom line over human lives.